Dew probably doesn't believe that per se.. His philosophy of biotech investing is different from other boards. Dew isn't a trader but an investor for long term.. He has always made that abundantly clear.
Put yourself in the shoes of an FDA reviewer. Why would you take a chance on approving a newfangled cell-based therapy for a cosmetic indication when there are several biologically inert dermal fillers on the market for the same indication that are effective and very safe?
Market Data 
Markets 
AI
